Bella Zhou China

戴德梁行 国际五大行之一
Website:
Cushman.com
Partnering Objectives
Headquartner in China
Cushman
Associate director 

Min Zhou China

Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Partnering Objectives
Headquartner in China
Hainan Haiyao Co. , Ltd
BD Director 

ping zhou China

Website:
www.jitri.org
Partnering Objectives
Headquartner in China
江苏省产业技术研究院
senior business manager 

Monica Zhou China

Established in Shenzhen Special Economic Zone in 1992;
Core competitiveness - A specialty company in digestion and intestinal microecology and a national level Hi-tech Enterprise.
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Shenzhen Wanhe Pharma
BD 

James Zhou China

A biotech company headquartered in China with clinically validated integrated platform for drug discovery and development.  We focus on oncology and inflammatory disease. There are four projects on Phase I clinical stage.

Partnering Objectives
Headquartner in China
Nanjing TransTherabio
Director 

HAN ZHOU China

Big pharm in China
Website:
www.cppharm.com
Headquartner in China
CP pharm
投资经理 

Dr. Bin Zhu United States

Simcere Pharmaceutical Group is a leading Chinese pharmaceutical company with full capability in discovery, development, manufacturing and commercialization. Simcere is actively looking for innovative drug candidates in multiple therapeutic areas. Simcere of America is a subsidiary of Simcere Pharmaceutical Group.
Company Size (Fulltime employees)
Year of foundation
1995
Please specify your partnering goal
CNS, Autoimmune and Oncology Products
Headquartner in China
Biotech/Pharma Asset Stage
Simcere of America
Senior Director 
Functionality

Dr. Qingsong Zhu United States

Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes.
Website:
insilico.com
Company Size (Fulltime employees)
Year of foundation
2014
Please specify your partnering goal
Collaborations on NMEs, therapeutic targets, AI-based generative chemistry
Headquartner in China
Insilico Medicine US Inc
COO 
Functionality

Dr. Wei Zhu United States

Allegro 3D is an emerging 3D printing and bioprinting company located in San Diego, a world hub for biotechnology. At the convergence of advanced additive manufacturing, stem cell biology and biomaterials, Allegro 3D’s expertise in bioprinting and biomaterials enables high-throughput manufacturing of advanced biomedical devices, cell matrices and precision human tissues for cell culture, drug screening, therapeutics and regenerative medicine.

Using the world’s most advanced bioprinting technologies developed at the University of California San Diego, Allegro 3D is poised to provide customers with transformational biofabrication solutions that will revolutionize healthcare innovations related to regenerative medicine, drug discovery, and biomedical research.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Looking for partners in drug discovery, regenerative medicine, and other 3D bioprinting applications.
Headquartner in China
Your Research Tool and Service name
Bioprinters, biomaterials, 3D tissues
Service Description
3D bioprinting Tissue engineering Drug screening Regenerative medicine
Target client type
Pharmaceutical, biotech, research institutes, hospitals
Allegro 3D, Inc.
CEO 
Functionality

John Zhu

6 Dimensions Capital Duality Biologics
PartnerFounder and CEO